Paradigm Biocapital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001855655

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 29 positions · Total reported value $5.03B · Top-10 concentration 78.6% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 54.3% · 7 new · 6 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, Paradigm Biocapital Advisors LP disclosed 29 equity positions with a combined reported value of $5.03B. The filing implies a focused portfolio: its ten largest positions account for 78.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M). By sector, the heaviest allocations are Health Care 99.7%, Other 0.3%. Versus the prior quarter, allocation shifted toward Health Care (+18.5pp) and away from Industrials (-0.8pp), Other (-17.7pp).

Versus the prior quarter, Paradigm Biocapital Advisors LP opened 7 new positions, trimmed 6 and fully exited 6, a turnover rate of 54.3% of positions. The portfolio's overlap with the prior quarter was 63% of names.

The largest new positions opened in Q3 2026 were BBIO ($154.49M), GPCR ($40.63M), MANE ($37.59M).

Of the 6 positions fully exited versus the prior quarter, the largest were NUVL ($731.67M), APGE ($209.23M), ALNY ($144.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • BBIO BRIDGEBIO PHARMA INC · $154.49M
  • GPCR STRUCTURE THERAPEUTICS INC · $40.63M
  • MANE VERADERMICS INC · $37.59M
  • ORIC ORIC PHARMACEUTICALS INC · $20.28M
  • ANIX ANIXA BIOSCIENCES INC · $19.65M
  • COAG HEMAB THERAPEUTICS HLDGS INC · $19.41M
  • TLGYF TCGX ACQUISITION CORP · $3.75M

Fully Exited (vs previous quarter)

  • NUVL NUVALENT INC · prev qtr: $731.67M
  • APGE APOGEE THERAPEUTICS INC · prev qtr: $209.23M
  • ALNY ALNYLAM PHARMACEUTICALS INC · prev qtr: $144.49M
  • EYPT EYEPOINT INC · prev qtr: $41.33M
  • MPLT MAPLIGHT THERAPEUTICS INC · prev qtr: $24.58M
  • LXEO LEXEO THERAPEUTICS INC · prev qtr: $19.44M

Insider Transactions (Form 4)

Latest Paradigm Biocapital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Paradigm Biocapital Advisors LP, based in New York, NY, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 29 positions worth $5.03B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-120338 (status: Approved), registered 2021-02-23
  • Regulatory AUM (Form ADV): $4.47B as of 2026-08-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 29 positions · $5.03B reported value (Q3 2026)
  • Top 10 holdings = 78.6% of reported value
  • Largest position: RVMD (REVOLUTION MEDICINES INC) at 25.4%
  • Average position size: $173.41M

Sector Tilt

  • Health Care 99.7%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 7 new, 13 added, 6 reduced, 6 exited
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively increasing exposure to high-growth biotech/healthcare names (e.g., INSM, VRDN, MBX) while trimming some established positions (RVMD, BLTE, TARS), suggesting a bullish stance on innovative therapeutics but selective profit-taking. 2. Key moves: - Added: GMAB (+3.28% wt), EWTX (+0.93% wt), SYRE (+1.51% wt), INSM (+3.47% wt), VRDN (+2.20% wt), MBX (+1.81% wt), ORKA (+0.31% wt). - Reduced: RVMD (-2.92% wt), BLTE (-0.30% wt), TARS (-0.33% wt). 3. Portfolio structure: Highly active, concentrated in Health Care (100% top-10), with aggressive growth bias (e.g., INSM +103% shares) and moderate risk appetite (top-10 holds 88.63% of $5B). 4. Per-holding one-liner: - RVMD: Revolution Medicines (oncology) - GMAB: Genmab A/S (antibody therapeutics) - EWTX: Edgewise Therapeutics (fibrosis) - SYRE: Spyre Therapeutics (inflammation) - INSM: Insmed Inc (antibiotics) - VRDN: Viridian Therapeutics (thyroid disease) - MBX: MBX Biosciences (unverified) - ORKA: Oruka Therapeutics (unverified) - BLTE: Belite Bio (eye diseases) - TARS: Tarsus Pharmaceuticals (ophthalmology) 5. Style summary: Aggressive biotech fund doubling down on high-growth clinical-stage names while trimming select large caps.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:02

Sector Allocation

Health Care 99.7%
Other 0.3%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 6.22M $1.28B 25.39%
25.39%
Reduce
2 14.14M $504.32M 10.03%
10.03%
Add
3 10.78M $437.61M 8.70%
8.70%
Add
4 4.46M $396.85M 7.89%
7.89%
Add
5 2.70M $307.72M 6.12%
6.12%
Add
6 12.41M $227.08M 4.51%
4.51%
Add
7 3.77M $221.17M 4.40%
4.40%
Add
8 2.49M $207.68M 4.13%
4.13%
Add
9 1.14M $193.96M 3.86%
3.86%
Reduce
10 2.30M $180.91M 3.60%
3.60%
Reduce
11 6.96M $173.69M 3.45%
3.45%
Add
12 2.35M $154.49M 3.07%
3.07%
New
13 2.14M $121.93M 2.42%
2.42%
Add
14 8.00M $117.25M 2.33%
2.33%
Reduce
15 6.05M $85.05M 1.69%
1.69%
Add
16 3.51M $76.77M 1.53%
1.53%
Add
17 8.72M $75.35M 1.50%
1.50%
Add
18 1.30M $40.63M 0.81%
0.81%
New
19 4.95M $40.06M 0.80%
0.80%
Hold
20 310.06K $37.59M 0.75%
0.75%
New
21 1.55M $36.50M 0.73%
0.73%
Hold
22 1.51M $20.28M 0.40%
0.40%
New
23 613.91K $19.65M 0.39%
0.39%
New
24 7.58M $19.47M 0.39%
0.39%
Add
25 629.35K $19.41M 0.39%
0.39%
New
26 889.58K $16.97M 0.34%
0.34%
Reduce
27 900.00K $13.28M 0.26%
0.26%
Hold
28 300.00K $3.75M 0.07%
0.07%
New
29 808.18K $2.98M 0.06%
0.06%
Reduce

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 70% R 70% F1 70% (modelled on 2026-Q2; 7/10 hit)

Low-confidence forecast This fund replaces about 32% of its Top-10 each quarter and backtests at F1 71% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (11 quarters)

Avg precision 71% · recall 71% · F1 71% · avg rank error 2.5 · Top-10 turnover 32%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 70% 70% 70% NUVL · ACLX · ARGX · IRON · VRDN · LEGN · OLMA · XENE · IMCR · CERE NUVL · ACLX · ARGX · IRON · CRNX · SRPT · IMCR · LEGN · ARVN · XENE
2024-Q2 60% 60% 60% NUVL · ACLX · ARGX · IRON · CRNX · SRPT · ARVN · IMCR · TARS · XENE NUVL · ARGX · ACLX · RVMD · SRPT · IRON · MRUS · CRNX · CERE · KURA
2024-Q3 70% 70% 70% NUVL · ARGX · RVMD · ACLX · SRPT · IRON · MRUS · CRNX · KURA · ASND NUVL · ARGX · RVMD · CRNX · MRUS · JANX · KURA · TARS · EWTX · IRON
2024-Q4 70% 70% 70% NUVL · RVMD · ARGX · MRUS · CRNX · JANX · KURA · TARS · EWTX · IRON NUVL · ACLX · ARGX · RVMD · JANX · TARS · EWTX · PCVX · ONC · CRNX
2025-Q1 70% 70% 70% NUVL · ACLX · ARGX · RVMD · JANX · TARS · PCVX · EWTX · ONC · MLTX NUVL · ACLX · RVMD · ONC · MRUS · TARS · JANX · CRNX · PCVX · IRON
2025-Q2 90% 90% 90% NUVL · ACLX · RVMD · ONC · MRUS · TARS · JANX · PCVX · CRNX · COGT NUVL · ACLX · MRUS · RVMD · TARS · PCVX · ONC · EWTX · COGT · JANX
2025-Q3 70% 70% 70% NUVL · ACLX · MRUS · RVMD · PCVX · TARS · EWTX · COGT · ONC · CRNX NUVL · ACLX · RVMD · TARS · PCVX · ABVX · GMAB · CRNX · XBI · EWTX
2025-Q4 80% 80% 80% NUVL · ACLX · RVMD · TARS · PCVX · ABVX · GMAB · EWTX · CRNX · XBI NUVL · RVMD · ACLX · GMAB · TARS · ABVX · OLMA · PCVX · XBI · CDTX
2026-Q1 70% 70% 70% RVMD · NUVL · ACLX · GMAB · TARS · XBI · PCVX · OLMA · ABVX · EWTX ACLX · RVMD · NUVL · PCVX · EWTX · GMAB · INSM · TARS · BLTE · ERAS
2026-Q2 60% 60% 60% ACLX · RVMD · NUVL · PCVX · GMAB · EWTX · INSM · TARS · BLTE · ERAS RVMD · NUVL · EWTX · GMAB · SYRE · APGE · ORKA · TNGX · BLTE · ERAS
2026-Q3 ★ 70% 70% 70% RVMD · NUVL · EWTX · GMAB · SYRE · TNGX · APGE · ORKA · BLTE · TARS RVMD · GMAB · EWTX · SYRE · INSM · VRDN · MBX · ORKA · BLTE · TARS

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

Barra Factor Attribution

The disclosed long US equity book from the 2026-Q3 13F is held at its report-date weights and decomposed over 2026-09-30 ~ 2026-11-16. The model uses 16 Barra style factors plus GICS sector dummies, WLS cross-sectional factor returns and an EWMA factor covariance for risk. The “portfolio” is the visible 13F book, not the fund's true NAV.

13F periodQ3 2026 Attribution quarterQ4 2026 (in progress) Window2026-09-30 → 2026-11-16 Trading days33 Holdings5 Model coverage100.0%

The quarter is not complete yet; the window ends at the latest available price date, 2026-11-16, and will update as prices arrive.

Portfolio return-10.82%Buy & hold
QQQ synthetic benchmark-17.01%Liquidity weighted
Excess return+6.19%vs benchmark
Barra annualised vol55.8%Model estimate
Realised vol48.7%Annualised in window
Weighted beta1.01Raw exposure
Factor / specific risk34% / 66%Share of variance
Top-10 concentration100.0%Of reported value
Portfolio value (start = 100)78.485.091.798.3105.010-0110-2311-16Paradigm Biocapital Advisors LPQQQ syntheticLiquid universe EW
Start = 100. Red = portfolio, dark = QQQ synthetic benchmark, dashed grey = equal-weight model universe.

1. Performance

Metric Value Note
Portfolio return (buy & hold)-10.82%Disclosed long book
QQQ synthetic benchmark-17.01%Liquidity-weighted constituents
Model universe, equal weight-1.70%Opportunity-cost reference
Excess return+6.19%Portfolio − benchmark
Arithmetic return sum-9.92%Difference vs compounded is the cross term
Weighted raw beta1.01Weighted holding betas
Realised volatility (annualised)48.66%Daily returns in window
Barra model volatility (annualised)55.75%Factor + specific
Factor share of variance33.7%Barra factors
Specific share of variance66.3%Stock residuals
Reported value$1.95B13F long US equity

2. Return attribution

The -9.92% arithmetic return splits into style factors, sector factors and specific return; the table is sorted by contribution.

Factor group Factors Contribution Share of |return|
Size & Liquidity 6 +3.68% 37.1%
Momentum & Growth 3 -12.03% -121.2%
Volatility & Tail Risk 7 +5.41% 54.5%
Industry 12 +6.98% 70.4%
Specific 1 -13.97% -140.8%
Return attribution (style + industry, %)-12.1-6.0+0.0+6.0+12.1Non-linear Size+0.53Leverage (Downside Vol)+0.53Mid Cap+0.64Beta+0.65Short-term Reversal+0.84Turnover+1.26Size+1.60Growth-1.69Skewness-3.04Kurtosis+3.30Historical Volatility-4.11Health Care+6.98Residual Volatility+8.11Momentum-11.18
Factor Type Exposure Factor return Contribution Share of |return|
Residual Volatility Style +2.46 +3.29% +8.11% 81.8%
Health Care Industry +1.00 +6.98% +6.98% 70.4%
Kurtosis Style +0.44 +7.51% +3.30% 33.2%
Size Style -0.82 -1.95% +1.60% 16.1%
Turnover Style -0.26 -4.80% +1.26% 12.7%
Short-term Reversal Style +0.96 +0.87% +0.84% 8.5%
Beta Style +0.15 +4.44% +0.65% 6.6%
Mid Cap Style -0.33 -1.94% +0.64% 6.5%
Leverage (Downside Vol) Style -0.31 -1.71% +0.53% 5.3%
Non-linear Size Style +0.52 +1.01% +0.53% 5.3%
Amihud Illiquidity Style +0.67 -0.45% -0.30% -3.0%
Growth Style -0.97 +1.75% -1.69% -17.0%
Skewness Style +0.69 -4.39% -3.04% -30.6%
Historical Volatility Style +0.29 -14.00% -4.11% -41.4%
Momentum Style +2.80 -4.00% -11.18% -112.7%
Specific Specific — — -13.97% -140.8%

3. Risk attribution

Annualised volatility is 55.75%; factor risk explains 33.7% of variance and specific risk 66.3%. A negative variance contribution means the factor is negatively correlated with the rest of the book and acts as a partial hedge.

Risk attribution (share of variance, %)-71.6-35.8+0.0+35.8+71.6Growth-1.29Non-linear Size-0.60Historical Volatility-0.39Skewness-0.21Leverage (Downside Vol)+0.28Amihud Illiquidity+0.42Kurtosis+0.65Beta+0.74Size+1.10Short-term Reversal+1.79Residual Volatility+5.53Health Care+9.02Momentum+16.66Specific+66.34
Factor Type Exposure Share of variance Vol contribution Share of vol
Specific Specific — 66.3% +36.99% 37.0%
Momentum Style +2.80 16.7% +9.29% 9.3%
Health Care Industry +1.00 9.0% +5.03% 5.0%
Residual Volatility Style +2.46 5.5% +3.08% 3.1%
Short-term Reversal Style +0.96 1.8% +1.00% 1.0%
Size Style -0.82 1.1% +0.61% 0.6%
Beta Style +0.15 0.7% +0.41% 0.4%
Kurtosis Style +0.44 0.7% +0.36% 0.4%
Amihud Illiquidity Style +0.67 0.4% +0.23% 0.2%
Leverage (Downside Vol) Style -0.31 0.3% +0.16% 0.2%
Skewness Style +0.69 -0.2% -0.12% -0.1%
Historical Volatility Style +0.29 -0.4% -0.22% -0.2%
Non-linear Size Style +0.52 -0.6% -0.33% -0.3%
Growth Style -0.97 -1.3% -0.72% -0.7%

4. Style exposures

Standardised z-scores; positive means the book leans toward that style versus the model universe, negative means underweight.

Style exposures (z-score)-1.3-0.20.92.03.2Max DrawdownKurtosisSkewnessLeverage (Downside Vol)GrowthTurnoverAmihud IlliquidityLiquidityHistorical VolatilityResidual VolatilityShort-term ReversalMomentumBetaMid CapNon-linear SizeSizePortfolioQQQ benchmark
Style factor Portfolio QQQ benchmark Difference
Size -0.82 +2.10 -2.92
Non-linear Size +0.52 +1.68 -1.15
Mid Cap -0.33 +0.13 -0.46
Beta +0.15 +1.29 -1.15
Momentum +2.79 +0.72 +2.08
Short-term Reversal +0.96 -0.64 +1.60
Residual Volatility +2.46 -0.40 +2.87
Historical Volatility +0.29 +0.86 -0.57
Liquidity -0.14 +0.11 -0.25
Amihud Illiquidity +0.67 +1.16 -0.49
Turnover -0.26 +0.21 -0.47
Growth -0.97 +0.58 -1.55
Leverage (Downside Vol) -0.31 +0.14 -0.45
Skewness +0.69 +0.24 +0.45
Kurtosis +0.44 +0.21 +0.22
Max Drawdown +0.02 -0.08 +0.10

5. Industry allocation & Brinson

Industry allocation (weight, %)-10.020.050.080.0110.0Information TechnologyCommunication ServicesUtilitiesConsumer StaplesConsumer DiscretionaryIndustrialsHealth CarePortfolioQQQ benchmark
Sector Portfolio Benchmark Portfolio ret Benchmark ret Allocation Selection Interaction Total
Information Technology 0.0% 73.6% +0.00% -22.33% +3.83% +16.44% -16.44% +16.44%
Communication Services 0.0% 2.6% +0.00% -17.64% +0.01% +0.46% -0.46% +0.46%
Utilities 0.0% 0.8% +0.00% +11.13% -0.22% -0.09% +0.09% -0.09%
Consumer Staples 0.0% 0.8% +0.00% +15.26% -0.27% -0.13% +0.13% -0.13%
Consumer Discretionary 0.0% 8.8% +0.00% +3.76% -1.84% -0.33% +0.33% -0.33%
Industrials 0.0% 11.1% +0.00% +4.36% -2.39% -0.48% +0.48% -0.48%
Health Care 100.0% 1.7% -10.75% +8.29% +24.98% -0.33% -18.71% -10.89%
Total +23.98% +15.51% -34.55% +4.95%

6. Holdings & contribution

Symbol Name Sector Weight Return Contribution QoQ
RVMD REVOLUTION MEDICINES INC Health Care 65.36% -18.70% -12.22% Reduce
INSM INSMED INC Health Care 15.75% +7.66% +1.21% Add
TNGX TANGO THERAPEUTICS INC Health Care 8.89% -3.13% -0.28% Add
BBIO BRIDGEBIO PHARMA INC Health Care 7.91% +17.57% +1.39% New
GPCR STRUCTURE THERAPEUTICS INC Health Care 2.08% -40.61% -0.84% New
Contribution rank Symbol Sector Weight Return Contribution
1 BBIO Health Care 7.91% +17.57% +1.39%
2 INSM Health Care 15.75% +7.66% +1.21%
3 TNGX Health Care 8.89% -3.13% -0.28%
4 GPCR Health Care 2.08% -40.61% -0.84%
5 RVMD Health Care 65.36% -18.70% -12.22%

7. Conclusions

  1. Over the attribution window 2026-09-30 → 2026-11-16 (33 trading days), the reported portfolio returned -10.82%, versus -17.01% for the QQQ synthetic benchmark — an excess of +6.19%.
  2. Return attribution: the largest positive style/industry contributions came from Residual Volatility +8.11%, Health Care +6.98%, Kurtosis +3.30%; the largest drags came from Momentum -11.18%, Historical Volatility -4.11%, Skewness -3.04%. Specific (stock-level) return contributed -13.97%.
  3. Risk attribution: Barra model volatility is 55.75% annualised; factor risk explains 34% of variance and specific risk 66%. The largest factor risk sources are Momentum 16.7%, Health Care 9.0%, Residual Volatility 5.5%.
  4. Style tilt: size -0.82, momentum +2.79, volatility +0.29, liquidity -0.14; the weighted raw beta is 1.01. Positive z-scores mean the portfolio leans toward that style versus the cross-section.
  5. Industry: the largest overweight versus the benchmark is Health Care (+98.3 pp), the largest underweight is Information Technology (-73.6 pp). Allocation contributed +23.98%, selection +15.51% and interaction -34.55%.
  6. Concentration: the top-10 positions are 100.0% of the attributed portfolio and the model covers 100.0% of its value with full style exposures. This is a high-conviction, long-only 13F book — not the fund's complete NAV.
Methodology & caveats
  • 13F discloses long US equity (including some options) only; cash, shorts and non-US positions are absent. This is not the fund's true NAV.
  • Weights are the report-date reported values and stay fixed over the window (buy & hold); intra-quarter trading and flows are not captured.
  • Factor exposures are measured at quarter end and held through the next quarter; style factors are cross-sectionally orthogonalised and read as incremental exposures.
  • The database has no share-count data, so size and liquidity use dollar volume (price × volume) as a proxy; Size is closer to “traded-value scale”.
  • Factor returns come from a WLS cross-sectional regression on the model universe; risk is annualised, and some factor variance contributions can be negative.
  • 13F filings lag by up to 45 days, so the stretch from the report date to the filing date was not actionable in real time.
  • Sector mapping uses one consistent GICS level-1 scheme for both the portfolio and the benchmark.

FAQ

What did Paradigm Biocapital Advisors LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Paradigm Biocapital Advisors LP reported 29 equity positions worth $5.03B in aggregate; its largest disclosed positions were RVMD ($1.28B), GMAB ($504.32M), EWTX ($437.61M).

How large is Paradigm Biocapital Advisors LP's portfolio?

Paradigm Biocapital Advisors LP reported $5.03B of long equity holdings across 29 positions as of 2026-Q3. Top-10 holdings account for 78.6% of reported value.

What is Paradigm Biocapital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/paradigm-biocapital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →